Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Jul 08, 2026
LyondellBasell Industries (LYB) Stock Falls -15.3% Over 30 Days as Index Removal and Analyst Downgrades Hit Hard

LyondellBasell Industries (LYB) Stock Falls -15.3% Over 30 Days as Index Removal and Analyst Downgrades Hit Hard

Key Takeaways

  • LyondellBasell shares fell approximately 15.3% over the past 30 days, dropping from $64.50 on June 5 to $54.60 on July 7, 2026, as multiple headwinds converged on the stock.
  • The decline was amplified by the company's removal from the Russell 1000 Defensive Index suite on June 27, triggering repositioning by institutional and rules-based funds.
  • Analyst price target cuts from Royal Bank of Canada, Citigroup, and others during the period added downward pressure, with RBC slashing its target from $94 to $65.
  • Broader concerns about global petrochemical demand, lingering overcapacity, and the sustainability of war-related margin benefits weighed on investor sentiment.
  • Over the quarter, the stock has declined roughly 27%, retreating sharply from its 52-week high of $83.94 reached on March 31, 2026.

Understanding LyondellBasell’s Business and Market Position

LyondellBasell Industries N.V. is one of the world's largest independent chemical companies, operating across five segments: Olefins and Polyolefins - Americas, Olefins and Polyolefins - Europe/Asia/International, Intermediates and Derivatives, Advanced Polymer Solutions, and Technology. The company produces polyethylene, polypropylene, propylene oxide, oxyfuels, and advanced polymers used in packaging, automotive, construction, electronics, and consumer goods. With a market capitalization of approximately $17 billion, LYB is a large-cap materials stock followed closely by investors for its sensitivity to global petrochemical cycles, feedstock costs, and macroeconomic demand trends. The company's cost-advantaged U.S. Gulf Coast assets and its portfolio transformation strategy—including the recent sale of four European sites—are central to its long-term investment narrative.

LYB Stock Performance: 30-Day Decline Compared to the Quarter

Over the last 30 days, LYB shares declined from $64.50 at the close on June 5, 2026, to $54.60 on July 7, 2026—a drop of approximately 15.3%. The selloff was not a single-day event but rather a persistent grind lower, with the stock recording a seven-day losing streak in late June that alone accounted for a cumulative decline of roughly 13%. The stock broke below its 50-day simple moving average in late May and has remained beneath that level throughout the period, while still trading below its 200-day moving average.

Zooming out to the quarterly view, the decline is even steeper. From its 52-week high of $83.94 on March 31, 2026, LYB has fallen approximately 35%. The stock entered the second quarter with strong momentum, buoyed by tightening petrochemical supply due to the Middle East conflict and a Q1 earnings beat. However, that momentum reversed sharply as the quarter progressed, with the stock giving back nearly all of its year-to-date gains. The three-month decline of roughly 27% stands in stark contrast to the S&P 500, which posted gains over the same period.

Factors Behind the Recent 30-Day Selloff in LYB

Several converging factors drove LYB's sharp decline over the past 30 days. The most significant catalyst was the company's removal from the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index on June 27, 2026. This reclassification forced rules-based funds and institutional portfolios benchmarked to these defensive indices to rebalance, creating sustained selling pressure. The removal reflected deteriorating metrics in LYB's financial profile, including a 2025 net loss of $745 million and a payout ratio that had turned deeply negative.

Analyst actions compounded the negative sentiment. Royal Bank of Canada lowered its price target from $94 to $65 on July 1, while Citigroup reduced its target from $80 to $67 in late June. Goldman Sachs maintained a sell rating with a $75 target. Weiss Ratings downgraded LYB from "hold" to "sell" on June 24. These revisions highlighted concerns about the durability of petrochemical margin improvements and the company's ability to sustain its reduced dividend.

Insider selling activity also weighed on confidence, with approximately $0.7 million in insider sales recorded over the prior three months and no corresponding buying activity. Additionally, broader macroeconomic uncertainty—including tariff risks, fluctuating crude oil prices, and questions about the pace of global capacity rationalization—kept buyers on the sidelines. While the Middle East conflict has steepened the global petrochemical cost curve in LYB's favor, investors increasingly questioned whether those benefits would persist long enough to offset structural headwinds.

Quarterly Performance Drivers and Market Reassessment

The quarterly decline of roughly 27% reflects a broader reassessment of LYB's risk-reward profile. The stock had rallied sharply earlier in 2026, gaining over 50% year-to-date by late March, as investors priced in the earnings upside from Middle East supply disruptions. The company's Q1 2026 results, reported on May 1, showed adjusted EPS of $0.49—beating estimates by $0.18—and EBITDA excluding identified items of $615 million, nearly 50% above the prior quarter. Management guided for significant sequential improvement in Q2, citing tighter supply dynamics and favorable pricing trends.

Despite the strong operational performance, the market began to focus on risks that the earnings beat had masked. Revenue of $7.2 billion missed analyst estimates of $7.53 billion, declining 6.3% year-over-year. The 50% dividend cut announced earlier in the year—from $1.37 to $0.69 per share—continued to weigh on income-oriented investors. The company's 2025 net loss of $745 million and a payout ratio of -237% underscored the financial strain that preceded the cut. As the quarter progressed, concerns about global overcapacity, particularly in polypropylene, and the potential for demand destruction if polymer prices rose too far, eroded confidence in the sustainability of the margin recovery. The Russell index removal in late June served as a culminating event that crystallized these concerns into accelerated selling.

One Tool That Has Helped Me Navigate Similar Situations

In volatile market environments like the one currently affecting LYB, I often look to data-driven resources for additional perspective. Tickeron’s AI Trading Bots provide a selection of AI-powered strategies that analyze thousands of tickers using technical analysis, pattern recognition, and momentum signals. These tools adapt to changing conditions and highlight approaches that have shown effectiveness in real time, offering a useful complement to traditional fundamental research when assessing how stocks like LYB might behave going forward.

What to Watch for LYB Going Forward

Looking ahead, several factors will determine whether LYB can stabilize and recover. The company's second-quarter 2026 earnings, scheduled for release on July 31, will be a critical checkpoint. Management guided for significant sequential improvement, and investors will scrutinize whether polyethylene and polypropylene pricing gains translated into margin expansion, and whether the Bayport PO/TBA facility restart progressed as planned. Any deviation from guidance could trigger further repositioning.

Geopolitical developments in the Middle East remain a wildcard. CEO Peter Vanacker stated the supply disruption would persist for "multiple quarters, definitely not months," but any progress toward de-escalation could rapidly unwind the cost-curve advantages that have supported LYB's North American and European assets. On the structural side, progress on China's anti-involution policies and the pace of global ethylene capacity rationalizations will shape the medium-term supply-demand balance. The company's Cash Improvement Plan, targeting $500 million in incremental cash flow for 2026, and the integration of the European asset sales will also be closely monitored as indicators of management's ability to strengthen the balance sheet and defend the reduced dividend. Finally, macroeconomic signals—including interest rate trajectories, consumer confidence, and durable goods demand—will influence the demand outlook for LYB's core polymer products.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LYB

LYB in upward trend: 10-day moving average moved above 50-day moving average on August 07, 2026

The 10-day moving average for LYB crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 10, 2026. You may want to consider a long position or call options on LYB as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

LYB moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYB advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 197 cases where LYB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LYB moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LYB broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.044) is normal, around the industry mean (7.001). P/E Ratio (98.766) is within average values for comparable stocks, (39.393). Projected Growth (PEG Ratio) (1.526) is also within normal values, averaging (2.393). LYB's Dividend Yield (0.061) is considerably higher than the industry average of (0.019). P/S Ratio (0.697) is also within normal values, averaging (70.976).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LYB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.06B. The market cap for tickers in the group ranges from 47 to 224.76B. LIN holds the highest valuation in this group at 224.76B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. CITR experienced the highest price growth at 21%, while LWLG experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 58
Price Growth Rating: 51
SMR Rating: 77
Profit Risk Rating: 81
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
LYB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of petrochemicals

Industry ChemicalsSpecialty

Profile
Details
Industry
Chemicals Specialty
Address
One Vine Street
Phone
+44 2072202600
Employees
20000
Web
https://www.lyondellbasell.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.